Skip To Main Content

Actualización normativa

En un entorno en constante cambio como el sistema de salud, es fundamental mantenerse al día con las nuevas normativas que afectan tanto a profesionales como a pacientes. En este espacio encontrará las leyes, decretos, resoluciones y acuerdos relacionados con el sistema de salud dinámico y en evolución.

También encontrará resúmenes, análisis y todo lo relacionado con la más reciente normatividad, para comprender el posible impacto de los cambios hacia los diferentes actores del sistema.

Ordenar por
Cumulative Life Course Impairment (CLCI) in Atopic Dermatitis

Cumulative Life Course Impairment (CLCI) in Atopic Dermatitis

Cumulative Life Course Impairment (CLCI) in Atopic Dermatitis

Cumulative Life Course Impairment (CLCI) in Atopic Dermatitis

Cumulative Life Course Impairment (CLCI) in Atopic Dermatitis

Cumulative Life Course Impairment (CLCI) in Atopic Dermatitis

Advancing Therapy in Type 2 Diabetes: The Soli-D Trial

Advancing Therapy in Type 2 Diabetes: The Soli-D Trial

Instruktážní animované video - aplikace nízkomolekulárního heparinu

Instruktážní animované video - aplikace nízkomolekulárního heparinu

EAS Highlights 2025

EAS Highlights 2025

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP

An expert panel convened by EPOS2020 and EUFOREA proposed standardized definitions for disease control, remission, and progression in CRSwNP. This initiative aims to harmonize and optimize the standard of care for patients with CRSwNP.

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP

An expert panel convened by EPOS2020 and EUFOREA proposed standardized definitions for disease control, remission, and progression in CRSwNP. This initiative aims to harmonize and optimize the standard of care for patients with CRSwNP.

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP

An expert panel convened by EPOS2020 and EUFOREA proposed standardized definitions for disease control, remission, and progression in CRSwNP. This initiative aims to harmonize and optimize the standard of care for patients with CRSwNP.

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP

An expert panel convened by EPOS2020 and EUFOREA proposed standardized definitions for disease control, remission, and progression in CRSwNP. This initiative aims to harmonize and optimize the standard of care for patients with CRSwNP.

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP

An expert panel convened by EPOS2020 and EUFOREA proposed standardized definitions for disease control, remission, and progression in CRSwNP. This initiative aims to harmonize and optimize the standard of care for patients with CRSwNP.

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP

An expert panel convened by EPOS2020 and EUFOREA proposed standardized definitions for disease control, remission, and progression in CRSwNP. This initiative aims to harmonize and optimize the standard of care for patients with CRSwNP.

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

 

MAT-CO-2400825 V1.0 03/2024